ALX Oncology (ALXO) reported second-quarter 2026 financial results, including a GAAP net loss of $18.0 million, or $0.13 per basic and diluted share, compared with a GAAP net loss of $25.9 million, or $0.49 per basic and diluted share, in the year-ago period.
The clinical-stage biotechnology company said cash, cash equivalents and investments were $153.4 million as of June 30, 2026, and that it expects those funds to support planned operations through the first half of 2028.
- R&D expenses were $13.1 million for the quarter, down from $18.0 million in the prior-year period.
- G&A expenses were $5.1 million, compared with $5.5 million a year earlier.
- Topline data from 80 patients in the Phase 2 ASPEN-09-Breast trial of evorpacept are expected in mid-2027.
- Initial safety data from the Phase 1 ALX2004 trial in EGFR-expressing solid tumors remain on track for the second half of 2026.
- The company refinanced $10 million of existing debt and secured access to up to an additional $20 million through June 2028.
$ALXO Insider Trading Activity
$ALXO insiders have traded $ALXO stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ALXO stock by insiders over the last 6 months:
- JASON LETTMANN (CHIEF EXECUTIVE OFFICER) sold 12,311 shares for an estimated $26,714
- SHELLY WONG (SVP, FINANCE AND CAO) has made 0 purchases and 2 sales selling 2,307 shares for an estimated $4,823.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ALXO Hedge Fund Activity
We have seen 43 institutional investors add shares of $ALXO stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC added 13,011,849 shares (+inf%) to their portfolio in Q1 2026, for an estimated $26,088,757
- RA CAPITAL MANAGEMENT, L.P. added 13,011,849 shares (+inf%) to their portfolio in Q1 2026, for an estimated $26,088,757
- REDMILE GROUP, LLC added 4,699,470 shares (+143.9%) to their portfolio in Q1 2026, for an estimated $9,422,437
- DRIEHAUS CAPITAL MANAGEMENT LLC added 4,311,738 shares (+303.0%) to their portfolio in Q1 2026, for an estimated $8,645,034
- MARSHALL WACE, LLP added 3,730,840 shares (+14144.8%) to their portfolio in Q1 2026, for an estimated $7,480,334
- VENBIO PARTNERS LLC added 3,184,713 shares (+32.8%) to their portfolio in Q1 2026, for an estimated $6,385,349
- 5AM VENTURE MANAGEMENT, LLC added 3,057,325 shares (+inf%) to their portfolio in Q1 2026, for an estimated $6,129,936
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
